virpax pharmaceuticals specializes in developing new drug delivery systems across various indications to increase compliance and maximize the ability to achieve full therapeutic efficacy. we develop branded pharmaceutical products for pain management by using cutting-edge technology to enhance patients' quality of life, all while creating value for our investors and partners. we are focused on becoming a global leader in non-opioid pain management by developing and delivering innovative pharmaceutical products to our customers. virpax is committed to collaborating with its network of u.s. and global partners to advance the development of proprietary drug platforms that will produce the next generation of branded pharmaceutical products.
Company profile
Ticker
VRPX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Virpax Pharmaceuticals Inc.
SEC CIK
Corporate docs
Subsidiaries
Novvae Pharmaceuticals, Inc. ...
IRS number
821510982
VRPX stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
5 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Apr 24
10-K
2023 FY
Annual report
26 Mar 24
8-K
Virpax Pharmaceuticals Reports 2023 Year-End Results
26 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 24
8-K
Virpax Pharmaceuticals Announces Reverse Stock
1 Mar 24
8-K
Submission of Matters to a Vote of Security Holders
29 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Dec 23
DEF 14A
Definitive proxy
7 Dec 23
8-K
Departure of Directors or Certain Officers
7 Dec 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 12.15 mm | 12.15 mm | 12.15 mm | 12.15 mm | 12.15 mm | 12.15 mm |
Cash burn (monthly) | 883.67 k | 700.80 k | 2.04 mm | 1.18 mm | 883.67 k | 700.80 k |
Cash used (since last report) | 5.87 mm | 4.65 mm | 13.53 mm | 7.80 mm | 5.87 mm | 4.65 mm |
Cash remaining | 6.29 mm | 7.50 mm | -1.38 mm | 4.35 mm | 6.29 mm | 7.50 mm |
Runway (months of cash) | 7.1 | 10.7 | -0.7 | 3.7 | 7.1 | 10.7 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 1 |
Closed positions | 5 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 730.71 mm |
Total shares | 3.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Anthony P. Mack | 2.73 mm | $0.00 |
Sabby Management | 400.00 k | $432.00 mm |
PNC PNC Financial Services | 100.88 k | $108.95 mm |
Renaissance Technologies | 89.35 k | $97.00 k |
Geode Capital Management | 66.04 k | $71.98 mm |
Vanguard | 65.15 k | $70.36 mm |
NTRS Northern Trust | 15.22 k | $16.44 mm |
Two Sigma Securities | 11.95 k | $12.91 mm |
Quantum Private Wealth | 10.00 k | $10.80 mm |
Tower Research Capital | 5.43 k | $5.87 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 24 | Eric Floyd | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3178 | 45,000 | 14.30 k | 45,000 |
29 Jan 24 | Barbara Ruskin | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3178 | 25,000 | 7.95 k | 25,000 |
29 Jan 24 | Jerrold Sendrow | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3178 | 25,000 | 7.95 k | 25,000 |
29 Jan 24 | Gerald W Bruce | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3178 | 125,000 | 39.73 k | 125,000 |
29 Jan 24 | Sheila Mathias | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3178 | 112,000 | 35.59 k | 112,000 |
News
12 Health Care Stocks Moving In Monday's Pre-Market Session
8 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
26 Mar 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Mar 24
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics And Scilex Pharmaceuticals
27 Feb 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
21 Feb 24
Press releases
Virpax Pharmaceuticals Reports 2023 Year-End Results
26 Mar 24
Thinking about buying stock in Vale SA, Virpax Pharmaceuticals, Paymentus, Futu Holdings, or Coya Therapeutics?
13 Mar 24
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price
27 Feb 24
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
27 Feb 24
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
7 Feb 24